JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models

被引：0
|
作者：
Hauptschein, Robert [1 ]
Woodcock, Simon [2 ]
Belfield, Andrew [2 ]
Mason, Helen [2 ]
Keppel, Dorottya [2 ]
Markova, Svetlana [1 ]
Kim, Kyuri [1 ]
Roller, Shane [1 ]
Phillips, Caroline [2 ]
Jones, Clifford D. [2 ]
Humphreys, Robin C. [1 ]
机构：
[1] Jazz Pharmaceut, Palo Alto, CA USA
[2] Redx Pharma, Manchester, Lancs, England
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2677
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in KRAS mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)
    Wu, Wenjuan
    Bhagwat, Shripad
    Kindler, Lisa
    McMillen, William
    Joseph, Sajan
    Buchanan, Sean
    Reinhard, Christoph
    Tiu, Ramon V.
    Peng, Sheng-Bin
    CANCER RESEARCH, 2019, 79 (13)
  • [32] The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs
    Mazzacurati, Lucia
    Lambert, Que T.
    Collins, Robert J.
    Koblish, Holly K.
    Ruggeri, Bruce
    Stubbs, Matthew C.
    Reuther, Gary W.
    BLOOD, 2017, 130
  • [33] Design and rationale of a first in human (FIH) phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF mutation positive solid tumors
    McKean, Meredith
    Kato, Shumei
    Spira, Alexander
    Xing, Yan
    Xie, Hao
    Buchbinder, Elizabeth
    Kobayashi, Ken
    Williams, Richard
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [34] A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
    Waizenegger, Irene C.
    Baum, Anke
    Steurer, Steffen
    Stadtmueller, Heinz
    Bader, Gerd
    Schaaf, Otmar
    Garin-Chesa, Pilar
    Schlattl, Andreas
    Schweifer, Norbert
    Haslinger, Christian
    Colbatzky, Florian
    Mousa, Sien
    Kalkuhl, Arno
    Kraut, Norbert
    Adolf, Guenther R.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (03) : 354 - 365
  • [35] OSI-930: Early clinical development of a potent inhibitor of KDR and Kit tyrosine kinases with anti-tumor activity in pre-clinical models
    Stephens, AW
    ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
  • [36] Identification of molecular determinants of response to GSK1120212B, a potent and selective MEK inhibitor, as a single agent and in combination in RAS/RAF mutant non-small cell lung carcinoma cells
    Liu, Li
    Hong, Shi
    Zhang, Vivian
    Gilmer, Tona
    CANCER RESEARCH, 2011, 71
  • [37] Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors
    Tolcher, Anthony W.
    Sullivan, Ryan J.
    Rasco, Drew W.
    Eroglu, Zeynep
    Lakhani, Nehal
    Kessler, Dana
    Usansky, Helen
    Reddy, Sanjeeva
    Denis, Louis J.
    Janku, Filip
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [38] Discovery of novel potent and selective inhibitors of PRMT5 with anti-tumor activity in hepatocellular carcinoma and lung pre-clinical models
    Gonzalvez, Francois
    Vandyck, Koen
    Debing, Yannick
    Gupta, Kusum
    Misner, Dinah
    Zhang, Qingling
    Liu, Jyanwei
    Stoycheva, Antitsa
    Stevens, Sarah
    Symons, Julian
    Beigelman, Leonid
    Raboisson, Pierre
    Deval, Jerome
    CANCER RESEARCH, 2020, 80 (16)
  • [39] Clinical BET Inhibitor RG6146 Demonstrates Potent and on-Target Activity in Pre-Clinical Models of Hematological Malignancy and Combines with Anti-CD20 and BCL-2 Inhibition to Provide Superior Efficacy
    Rueflibrasse, Astrid
    Friess, Thomas
    Lechner, Stephanie
    Wellinger, Lisa
    Brouwer, Jurriaan
    Pierceall, William E.
    BLOOD, 2017, 130
  • [40] Integrated analysis of clinical pharmacokinetics (PK), nonclinical PK/efficacy (E) and pharmacodynamic (PD)/E relationships, and translational PK/PD simulations to guide clinical dose and schedule of MLN2480, an oral investigational pan-RAF kinase inhibitor.
    Faucette, Stephanie
    Mettetal, Jerome
    Zhou, Xiaofei
    Chouitar, Jouhara
    Patel, Mayank
    Bargfrede, Michael
    Galvin, Katherine
    Bozon, Viviana
    Venkatakrishnan, Karthik
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345